In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
Icon non-executive chairman awarded RDS gold medal for outstanding leadership
An article published by The Irish Times featuring commentary from Ciarán Murray on his achievement of being awarded with the RDS gold medal for enterprise for his “outstanding professional and leadership skills”.
-
Ciarán Murray – an Icon of leadership in pharma sector
An article published by The Irish Times featuring commentary from Ciarn Murray on the growth of ICON and his career journey to achieve the RDS Gold Medal for Industry.
-
Oncology clinical trials in APAC
Although Asia Pacific (APAC) is sometimes referred to as a homogenous unit, it is a heterogeneous region, with divergent countries, languages, populations and cultures. The main pharmaceutical markets, Japan, China, South Korea, Taiwan and Australia, have different business, labor and regulatory environments, so the characteristics of clinical development also differ.
Clinical research in APAC is very well established, with high-quality research infrastructure, and some Centers of Excellence have leapfrogged the West, especially in IT and equipment. Many multinational pharmaceutical companies and CROs have been in the region for more than 20 years, so there is a great depth of experience to draw on.
In terms of the value of the pharmaceutical market, China and Japan are second and third in the world, respectively, after the US, which reflects their importance in the overall global market. In this article, we review some of the characteristics of clinical research in APAC and some of the factors affecting it, particularly in oncology.
-
Key Considerations for Disease Modifying Parkinson's Disease Trials
A thought leadership article by Peter Schueler and Haichen Yang on the key considerations for disease modifying parkinson's disease trials. This article is featured in Pharmaceutical Market Europe (PME).
-
How to use digital health in clinical trials to improve patient engagement
Read this Medical Design and Outsourcing article, written by Vicki Anastasi and Matthew McCarty, to discover how a unified patient experience, where patients can manage every aspect of their trial via a single one-touch access point (such as an integrated smart phone app), can work to optimise data collection and improve patient retention and engagement.
-
Precision medicine: Overcoming cost challenges
This is a thought leadership article published by PharmaTimes, written by Vicki Anastasi, on the cost challenges of precision medicine for payers, patients and physicians, and strategies to overcome them, drawing on research from the recently published 'Looking Ahead: The Future of Device Developers in Precision Medicine' whitepaper. This article discusses how the solutions are two-fold; requiring implementation of technologies to enhance treatment efficacy, coupled with the optimisation of value-based models.
-
New Unfoldings in Pharma Compliance
Read our Pharma Tech Outlook article featuring thought leader Tom O'Leary as he covers the impact of mHealth on pharma compliance, providing strategies to navigate upcoming disruptions, and highlighting best practice to ensure compliance for digital clinical trials.
-
Improving Pharma R&D Efficiency
A thought leadership article in Contract Pharma discussing the key findings from ICON's and Pharma Intelligence's survey of pharmaceutical executives and professionals which examined the key challenges of declining research and development (R&D) efficiency. The article explores the need for a holistic and integrated approach to improve clinical trial efficiencies.
-
Hybrid Study Designs & the Link Between RWE, Epidemiology
A Q&A article in Outsourcing Pharma featuring commentary from Kerina Bonar, discussing the challenges and advantages of hybrid study designs. The article explores how designing studies with epidemiological input can be beneficial for real world evidence generation and ensuring a study design is fit for purpose.
-
FDA Guidance on Communicating with Payers
This year The Food and Drug Administration (FDA) released two final guidance documents. Learn more in this Scrip article about the most significant provisions of these documents and the key takeaways for manufacturers with respect to sharing health economic data with payers.
